Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
10.77
-0.14 (-1.33%)
At close: Mar 9, 2026, 4:00 PM EDT
10.77
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Rallybio Employees
Rallybio had 25 employees as of December 31, 2024. The number of employees decreased by 18 or -41.86% compared to the previous year.
Employees
25
Change (1Y)
-18
Growth (1Y)
-41.86%
Revenue / Employee
$44,933
Profits / Employee
-$944,667
Market Cap
56.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| ImmuCell | 84 |
| BeyondSpring | 40 |
| LeonaBio | 26 |
| Entera Bio | 22 |
| NeurAxis | 21 |
| Edesa Biotech | 17 |
| Alterity Therapeutics | 9 |
RLYB News
- 6 days ago - Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript - Seeking Alpha
- 7 days ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 7 days ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 20 days ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 20 days ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 4 weeks ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 4 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 5 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire